Table 1 Demographic data, clinical characteristics and routine hematological and biochemical parameters of breast cancer patients and controls
|  | Control group (n = 30) | All patients (n = 62) | Localized stage (n = 13) | Regional stage (n = 29) | Metastatic stage (n = 20) |
|---|---|---|---|---|---|
Age (year) | 55 ± 10 | 52 ± 11 | 53 ± 10 | 54 ± 11 | 49 ± 13 |
BMI (Kg/m2) | 27 ± 6 | 28 ± 4.7 | 29.6 ± 4.7 | 27.6 ± 4.2 | 27.7 ± 5.6 |
Hemoglobin (g/dL) | 11.6 ± 2 | 11.5 ± 1.5 | 11.2 ± 1.1 | 11.8 ± 1.4 | 11.3 ± 1.8 |
Leukocytes (109/L) | 7.3 ± 1.8 | 7.1 ± 4.8 | 7.2 ± 2.4 | 7.1 ± 2.8 | 7.1 ± 5 |
Platelets (109/L) | 270 ± 62 | 242 ± 96 | 262 ± 65 | 264 ± 98 | 198 ± 98 |
PT (% of prothrombin) | 100 ± 8 | 92 ± 8.3 | 94 ± 6 | 95 ± 7 | 89 ± 11 |
aPTT ratio | 1 ± 0.2 | 0.9 ± 0.06 | 0.9 ± 0.05 | 0.9 ± 0.06 | 0.9 ± 0.08 |
Fibrinogen (g/L) | 3.9 ± 0.6 | 4.4 ± 1.2 | 4 ± 0.8 | 4.7 ± 1.4 | 4.4 ± 1.1 |
CRP (mg/L) | - | 14.5 ± 50 | 32 ± 99 | 7 ± 20 | 10 ± 15 |
ALAT (IU/L) | - | 25 ± 13 | 30 ± 16 | 24 ± 10 | 25 ± 15 |
ASAT (IU/L) | - | 36 ± 23 | 31 ± 18 | 34 ± 17 | 43 ± 32 |
Creatinine (μmol/L) | - | 65 ± 17 | 67 ± 23 | 67 ± 17 | 62 ± 13 |
Urea (mg/dL) | - | 5 ± 2 | 5 ± 1.6 | 5.5 ± 2.7 | 5 ± 2.2 |
Time since diagnosis (n) | Â | Â | Â | Â | Â |
0-6 months | Â | 27 | 8 | 15 | 4 |
6-12 months | Â | 10 | 2 | 7 | 1 |
12-36 months | - | 13 | 3 | 5 | 5 |
> 36Â months | Â | 12 | 0 | 2 | 10 |
Cardiovascular risk factors (n) | Â | Â | Â | Â | Â |
-Hypertension | no | 14 | 3 | 9 | 2 |
-Varicose veine | no | 8 | 1 | 6 | 1 |
-Hyperlipidemia | no | 4 | 1 | 3 | 0 |
-Diabetes | no | 6 | 1 | 3 | 2 |